Open this publication in new window or tab >> Tel Aviv University, School of Health Professions, Department of Nursing Sciences, Tel Aviv, Israel.
University of Applied Sciences and Arts of Southern Switzerland (SUPSI), Department of Business Economics, Health and Social Care, Manno, Switzerland.
University of South Florida, College of Public Health, Tampa, FL, United States.
University of Haifa, Faculty of Social Welfare and Health Sciences, Haifa, Israel.
University of South Florida, Department of Communication, Tampa, FL, United States.
University of Michigan, School of Social Work, Ann Arbor, MI, United States.
University of Bologna, IRCCS AOUBO, Medical Genetics Unit, Bologna, Italy.
Umeå University, Faculty of Medicine, Department of Nursing. Region Västerbotten, The Federation of Cancer Centers North, Umeå, Sweden.
Lund University, Division of Oncology, Department of Clinical Sciences Lund, Lund, Sweden.
Yonsei University, College of Nursing, Seoul, South Korea.
The Netherlands Cancer Institute, Department of Clinical Genetics, Amsterdam, The Netherlands.
University of Applied Sciences and Arts of Southern Switzerland (SUPSI), Department of Business Economics, Health and Social Care, Manno, Switzerland.
Zealand University Hospital, Medical Department, Roskilde, Denmark.
University of Exeter, Department of Clinical and Biomedical Sciences, Exeter, United Kingdom.
Umeå University, Faculty of Medicine, Department of Nursing.
University of Southern California, Medical Oncology, Los Angeles, CA, United States.
Umeå University, Faculty of Medicine, Department of Diagnostics and Intervention.
University of Rochester, School of Nursing, Rochester, NY, United States.
University of Illinois Chicago, Cancer Center, Chicago, IL, United States.
University of Michigan, Internal Medicine, Gastroenterology, Ann Arbor, MI, United States.
University of Manchester, Genomic Medicine, Manchester, United Kingdom.
Nanyang Technological University, Lee Kong Chian School of Medicine, Singapore.
Vanderbilt University, Vanderbilt-Ingram Cancer Center, Nashville, TN, United States.
City of Hope National Medical Center, Division of Clinical Cancer Genomics, Department of Medical Oncology and Therapeutics Research, Duarte, CA, United States.
University of Basel, Department of Clinical Research, Basel, Switzerland.
Show others...
2026 (English) In: Public Health Genomics, ISSN 1662-4246, E-ISSN 1662-8063, Vol. 29, no 1, p. 209-217Article in journal (Refereed) Published
Abstract [en] Introduction: Improving access to genetic testing has increased the number of individuals identified with cancer genetic predisposition. Hereditary Breast and Ovarian Cancer (HBOC) and Lynch syndrome (LS) are key examples of high-risk hereditary cancer syndromes. Ensuring that carriers of germline pathogenic/likely pathogenic variants (GPVs) receive evidence-based risk counseling, surveillance and risk-reducing interventions remains a global challenge. Variations in implementation and reporting of international guidelines across healthcare systems contributes to this problem.
Methods: An international workshop on cancer genetic care held from March 12–15 2025 in Switzerland brought together 40 experts on this topic from 10 countries. The workshop combined evidence-based presentations with expert-led discussions and considered novel strategies, which were synthesized in key discussion points.
Results: Participants highlighted major inconsistencies in reporting age of initiation and uptake of surveillance, follow-up intervals, and uptake of risk-reducing interventions for carriers of GPV associated with genetic predisposition to cancer between and within countries. These differences are due to variations in available technology, insurance coverage, and sociocultural attitudes that shape national clinical guidelines. Participants emphasized the need for a standardized approach for reporting surveillance practices, including clear definitions of gene-specific recommendations, timing of follow-up, and alternatives when ideal resources are limited. In addition to these reporting issues, participants also noted the need for sustained outreach for lifelong follow-up surveillance of GPV carriers through digital as well as low-tech approaches.
Conclusion: Standardized reporting of surveillance and risk-reducing practices across countries may improve the quality and comparability of data in cancer genetic predisposition, reveal gaps in genetic care, and inform outreach strategies for engaging GPV carriers in lifelong cancer risk management.
Place, publisher, year, edition, pages
S. Karger, 2026
Keywords access to genetic services, systematic reporting, harmonization of reporting, healthcare systems, follow-up genetic care, HBOC, Lynch Syndrome
National Category
Nursing Cancer and Oncology Health Care Service and Management, Health Policy and Services and Health Economy
Identifiers urn:nbn:se:umu:diva-257136 (URN) 10.1159/000553075 (DOI) 001848318100001 () 42371863 (PubMedID) 2-s2.0-105046764519 (Scopus ID)
2026-08-042026-08-042026-09-07 Bibliographically approved